SHARE training FAQs

What is the SHARE program?
The SHARE (Starting Hizentra Administration with Resources and Education) program educates nurses and other clinicians on SCIg administration with Hizentra and provides information on best practices and training techniques that will optimize patient care.

Why do I need to register for the SHARE training program?
Registration is required so we can customize the experience for you.

How do I access SHARE training materials?
You can access SHARE training through the home page of this site. Registration is required.

What if my staff has already been trained on Vivaglobin^®?
In order to be adequately trained, it is recommended that your staff go through the full SHARE training and take the new exam. However, abbreviated training, which contains clinical information about how Hizentra differs from Vivaglobin, is available.

How long does SHARE training take?
It's hard to say exactly how long training will take because you will be able to move at your own pace. However, most people are able to finish in less than an hour.

Will my staff have to be retrained in the future?
Not necessarily, but it is a good idea for your staff to go through training periodically, especially if they don't train patients on a regular basis.

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra^®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.